Month: August 2025

NORCROSS, Ga., Aug. 14, 2025 (GLOBE NEWSWIRE) — CoreCard Corporation (NYSE: CCRD) (“CoreCard” or the “Company”), the leading provider of innovative credit technology solutions and processing services to the financial technology and services market, announced today its financial results for the quarter ended June 30, 2025. Financial Highlights for the three months ended June 30, 2025 Total revenues in the three-month period ended June 30, 2025, was $17.6 million compared to $13.8 million in the comparable period in 2024. In the following table, revenue is disaggregated by type of revenue for the three months ended June 30, 2025 and 2024:    Three Months Ended    June 30,(in thousands)   2025 2024License   $ − $ −Professional services     9,381   6,973Processing and maintenance     6,564   5,694Third party     1,649   1,130Total   $ 17,594 $ 13,797Income...

TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce and report the results of Q2 2025. Management Commentary: “Q2 marked another milestone in Avicanna’s journey, fueled by advancements in our pipeline and deeper engagement with the Canadian medical community. In Canada, we delivered growth across multiple commercial channels, underscoring the strength of our proprietary, high-margin portfolio. Achieving positive adjusted EBITDA for the first half of 2025 reflects the financial discipline and operational focus that continue to drive our performance. These results reinforce our ability to execute our strategy...

Second quarter 2025 GAAP net loss of $(13.2) million or $(0.60) per basic weighted average common share and  Distributable Earnings(1) of $3.4 million or $0.15 per basic weighted average common share Announces Intention to Convert from Mortgage REIT to BDC WEST PALM BEACH, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) — Advanced Flower Capital Inc. (Nasdaq: AFCG) (“Advanced Flower Capital”, “AFC” or the “Company”) today announced its results for the quarter ended June 30, 2025. AFC reported generally accepted accounting principles (“GAAP”) net loss of $(13.2) million or $(0.60) per basic weighted average common share and Distributable Earnings of $3.4 million or $0.15 per basic weighted average common share for the second quarter of 2025. “During the quarter, we focused on working through our non-accrual credits with the goal to achieve...

Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations completed enrollment, exceeding enrollment target by over 25%; top-line results on track for the first quarter of 2026 Top-line results for Phase 2 TOIVA trial evaluating QTORIN™ rapamycin for cutaneous venous malformations remain on track for the fourth quarter of 2025 QTORIN™ rapamycin has the potential to be the first approved therapy and standard of care in the U.S. for microcystic lymphatic malformations and cutaneous venous malformations Company plans to announce both a third clinical indication for QTORIN™ rapamycin and a second QTORIN™ platform candidate before year-end 2025 Cash and cash equivalents of $70.4 million as of June 30, 2025 are expected to fund operations...

– Received FDA approval for ZEVASKYN™ (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB) – – U.S. launch on track and first ZEVASKYN patient treatment expected in 3Q 2025, momentum building with strong patient interest at qualified treatment centers and referrals, positive insurance coverage established with multiple national and regional payers – – $226M in cash, cash equivalents, restricted cash and short-term investments as of June 30, 2025, expected to fund operations for over two years before accounting for anticipated ZEVASKYN revenue beginning in 3Q 2025 and projected profitability in 1H 2026 – CLEVELAND, Aug. 14, 2025 (GLOBE NEWSWIRE) —...

Following positive preclinical data, simufilam development to advance with a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsy Recent appointment of experienced neuroscience leaders to guide the clinical development strategy for simufilam Advanced settlement negotiations ongoing to resolve certain securities litigation; $31.25 million estimated loss contingency recorded in Q2 for resolution $112.4 million in cash and cash equivalents at June 30, 2025AUSTIN, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the...

Breakthrough Therapy designation granted for LX2006 based on interim data from Phase I/II trials demonstrating clinically meaningful improvements in cardiac and neurologic measures of Friedreich ataxia LX2006 selected for FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) program, created to facilitate CMC registrational readiness and support faster patient access Eight participants dosed in Phase I/II clinical trial (HEROIC-PKP2) of LX2020 for PKP2-ACM; interim clinical data update on track for second half of 2025 Strategic partnership announced with Perceptive Xontogeny Venture Funds and venBio Partners to advance non-viral, RNA-based therapeutics for genetic cardiac diseases $80 million equity financing to support development of clinical stage pipeline; cash, cash equivalents and investments in marketable...

Cash runway extended to deliver clinical program in GVHD and Ph2 results in 2L Gastric Cancer Department of Defense STTR Grant to advance INKTs in GVHD announced; program advancing New clinical grant awarded to launch AgenT-797 in GvHD clinical trial; target initiation 2H2025NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced financial results for the second quarter ended June 30, 2025, and provided a business update highlighting major clinical achievements, a strengthened balance sheet, and expanded funding to advance both oncology and immunology programs. “In Q2, we demonstrated the power of our platform with high impact clinical results, publication...